In a report released on September 30, Tyler Van Buren from TD Cowen maintained a Buy rating on Bicara Therapeutics Inc.. The company’s shares closed yesterday at $16.61.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Van Buren is an analyst with an average return of -0.2% and a 45.34% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and IDEAYA Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicara Therapeutics Inc. with a $31.67 average price target, which is a 90.67% upside from current levels. In a report released on September 29, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.
BCAX market cap is currently $906.3M and has a P/E ratio of -8.81.
Read More on BCAX:
Disclaimer & DisclosureReport an Issue
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
- Bicara Therapeutics initiated with a Buy at JonesResearch
- Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
- Bicara Therapeutics initiated with an Overweight at Piper Sandler
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)